Head to head
Novocure vs Abbott Laboratories
Side-by-side on the measures that matter, with a plain-English read. Full detail: NVCR · ABT
NVCR
Novocure
10.71+0.19%
1-year price shape — -7% over the period
Quant Rating D · 32/100
vs
ABT
Abbott Laboratories
103.00-0.84%
1-year price shape — -15% over the period
Quant Rating D · 22/100
1-year performance, rebased to 100
Abbott Laboratories edges it on the scoreable measures. Abbott Laboratories pays the highest dividend yield; Abbott Laboratories earns the most per share.
| NVCR | ABT | |
|---|---|---|
| Snapshot | ||
| Sector | Medical Devices | Medical Devices |
| Last price | 10.71 | 103.00 |
| Change today | +0.19% | -0.84% |
| 1-year return | -6.5% | -15.4% |
| Market cap | $1.25B | $178.39B |
| 52-week range | 9.82 – 21.45 | 80.89 – 126.70 |
| Valuation | ||
| P/E (TTM) | -10.10 | 38.29 |
| P/E percentile, own 5-yr range | 61st | 99th |
| P/B | 3.57 | 3.50 |
| Dividend yield | 0.00% | 2.41% |
| Profitability & growth | ||
| EPS (TTM) | -1.22 | 3.72 |
| Net profit (TTM) | $-142.64M | $6.44B |
| Revenue (TTM) | $725.39M | $48.23B |
| Provider revenue period date | 2026-09-29 | 2026-09-29 |
| Revenue growth (YoY) | +15.7% | +14.5% |
| Gross margin | 77.0% | 56.9% |
| Operating margin | -17.2% | 13.8% |
| Net margin | -16.8% | 9.7% |
| Free cash flow (TTM) | $-24.61M | $6.76B |
| Provider cash-flow period date | 2026-09-29 | 2026-09-29 |
| Ownership & sentiment | ||
| Institutional ownership | 89.2% | 81.2% |
| Insider activity (12mo) | 31 buy / 19 sell | 36 buy / 12 sell |
| Short interest (% of float) | 11.0% | 1.1% |
| Analyst consensus | 100% buy (3) | 93% buy / 7% hold (15) |
| Analyst price target | $27 (+149%) | $122 (+18%) |
| StockVane view | ||
| StockVane Quant Rating | D (32) | D (22) |
| Company | ||
| Employees | 1,605 | 115,000 |
| Founded | 2000 | 1900 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.